The serum level approach to individualization of drug dosage
- 1 January 1975
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 9 (1) , 1-8
- https://doi.org/10.1007/bf00613423
Abstract
The importance of individualizing the dosage of potent drugs in order to maximize their therapeutic effectiveness and safety is generally accepted. Whenever possible the dosage of a drug should be “titrated” directly in each patient against the intensity of its therapeutic or toxic actions. Unfortunately, for many drugs convenient clinical yardsticks of the intensity of their pharmacologic effects are lacking. Determination of the serum concentration of such compounds can help to guide adjustment of dosage during their therapeutic use. By measuring the serum level of drugs one bypasses the largest source of individual differences in doseeffect relationships — the pharmacokinetic variation between subjects. However, the relationship between the serum concentration of a drug and the intensity of its pharmacodynamic action is influenced by many other factors, which must always be considered in interpretation of serum levels. Therapeutic decisions should never be based solely on the serum concentration of a compound, nor can such measurements ever substitute for careful medical observation and judgement.Keywords
This publication has 30 references indexed in Scilit:
- Drug interactions in cardiovascular therapyAmerican Heart Journal, 1975
- Dosage of Theophylline in Bronchial AsthmaNew England Journal of Medicine, 1975
- Digitalis toxicity: Epidemiology and clinical use of serum concentration measurementsThe American Journal of Medicine, 1975
- Serum digitalis measurements in the assessment of digitalis resistance and sensitivityThe American Journal of Medicine, 1975
- Bioavailability of DrugsNew England Journal of Medicine, 1974
- Quinidine Elimination in Patients with Congestive Heart Failure or Poor Renal FunctionNew England Journal of Medicine, 1974
- Salicylate IntoxicationNew England Journal of Medicine, 1973
- BIOCHEMICAL AND GENETIC FACTORS REGULATING DILANTIN METABOLISM IN MAN*Annals of the New York Academy of Sciences, 1971
- GENETIC CONTROL OF DRUG LEVELS AND OF THE INDUCTION OF DRUG‐METABOLIZING ENZYMES IN MAN: INDIVIDUAL VARIABILITY IN THE EXTENT OF ALLOPURINOL AND NORTRIPTYLINE INHIBITION OF DRUG METABOLISMAnnals of the New York Academy of Sciences, 1971
- Relationship Between the Plasma Level of Diphenylhydantoin Sodium and Its Cardiac Antiarrhythmic EffectsCirculation, 1968